Nourish Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.05 Cr
as on 16-11-2024
- Company Age 11 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.90 Cr
as on 16-11-2024
- Revenue -11.49%
(FY 2023)
- Profit -19.26%
(FY 2023)
- Ebitda -185.33%
(FY 2023)
- Net Worth 51.42%
(FY 2023)
- Total Assets 63.33%
(FY 2023)
About Nourish Pharmaceutical
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.05 Cr.
The company currently has active open charges totaling ₹4.90 Cr.
Lilaram Asudani, Mohmmedali Saiyed, Mohmadpayam Kadri, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ2013PTC077469
- Company No.
077469
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2013
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Kheda, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Nourish Pharmaceutical?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohmadpayam Kadri  | Director | 12-Nov-2013 | Current |
| Lilaram Asudani | Director | 04-Oct-2021 | Current |
| Mohmmedali Saiyed | Director | 12-Nov-2013 | Current |
| Shenaz Saiyed | Director | 12-Nov-2013 | Current |
| Niti Pancholi | Director | 16-Oct-2020 | Current |
| Ruhan Kadri | Director | 12-Nov-2013 | Current |
Financial Performance of Nourish Pharmaceutical.
Nourish Pharmaceutical Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.49% decrease. The company also saw a substantial fall in profitability, with a 19.26% decrease in profit. The company's net worth Soared by an impressive increase of 51.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nourish Pharmaceutical?
In 2023, Nourish Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 21 Mar 2022 | ₹4.90 Cr | Open |
How Many Employees Work at Nourish Pharmaceutical?
Unlock and access historical data on people associated with Nourish Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nourish Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nourish Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
